论文部分内容阅读
目的探讨新型雌激素膜受体ER-α36和GPR30在乳腺癌中的表达及与乳腺癌临床病理特征间的关系。方法应用免疫组织化学方法检测该院2011年4月-2014年4月72例乳腺癌及41例相应癌旁正常乳腺组织中ER-α36及GPR30的表达,分析其与乳腺癌及其临床病理特征间的关系。结果 ER-α36、GPR30主要表达于乳腺上皮细胞的细胞膜和细胞浆;72例乳腺癌中ER-α36、GPR30表达率分别为43.1%(31/72)、52.8%(38/72);41例癌旁正常乳腺组织中ER-α36、GPR30表达率分别为68.3%(28/41)、53.7%(22/41)。ER-α36在乳腺癌中的表达低于正常乳腺组织(P<0.05);乳腺癌中ER-α36表达与淋巴结转移、患者年龄、病理分级、肿瘤分期及肿瘤大小无关(P>0.05)。GPR30表达在乳腺癌和正常乳腺组织相似(P>0.05);GPR30表达和肿瘤大小及淋巴结转移呈正相关(P<0.05),与其他临床指标无关(P>0.05)。本研究未发现ER-α36、GPR30表达之间的关系。结论新型雌激素膜受体ER-α36、GPR30在乳腺癌及癌旁组织中均有表达;ER-α36在乳腺癌中表达降低;GPR30和乳腺癌肿瘤大小及淋巴结转移等恶性指标有关。ER-α36、GPR30是乳腺癌发生发展的重要分子指标。
Objective To investigate the expression of estrogen receptor ER-α36 and GPR30 in breast cancer and its relationship with clinicopathological features. Methods Immunohistochemistry was used to detect the expression of ER-α36 and GPR30 in 72 cases of breast cancer from April 2011 to April 2014 and 41 cases of normal paracancer tissues adjacent to cancer. The correlation between the expression of ER-α36 and clinicopathological characteristics Relationship between. Results ER-α36 and GPR30 were mainly expressed in the cell membrane and cytoplasm of breast epithelial cells. The expression rates of ER-α36 and GPR30 in 72 cases of breast cancer were 43.1% (31/72) and 52.8% (38/72) respectively, and 41 cases The positive rates of ER-α36 and GPR30 in normal breast tissues were 68.3% (28/41) and 53.7% (22/41), respectively. The expression of ER-α36 in breast cancer was lower than that in normal breast tissues (P <0.05). The expression of ER-α36 in breast cancer was not associated with lymph node metastasis, age, pathological grade, tumor stage and tumor size (P> 0.05). The expression of GPR30 was similar to that of normal breast tissue (P> 0.05). The expression of GPR30 was positively correlated with tumor size and lymph node metastasis (P <0.05), but not with other clinical parameters (P> 0.05). This study found no relationship between the expression of ER-α36 and GPR30. Conclusions ER-α36 and GPR30 are both expressed in breast cancer and paracancerous tissues. The expression of ER-α36 is decreased in breast cancer and GPR30 is correlated with tumor size and lymph node metastasis in breast cancer. ER-α36, GPR30 is an important molecular indicator of the development of breast cancer.